Pathnostics: Samuel Riccitelli

Pathnostics' board has appointed Samuel Riccitelli as its CEO, effective July 29. He replaces Pathostics Cofounder David Pauluzzi, who will remain on the board. Riccitelli has more than 30 years of experience in global laboratory services and specialty testing, including stints at Becton Dickinson and Genoptix, where he was chief operating officer. More recently was president and CEO of Signal Genetics and Miragen Therapeutics.